Because many tumors have mutated p53, one potential strategy proposed for cancer gene therapy is the introduction of the wild-type p53 gene into tumor cells. One puzzling aspect of this approach is that currently available gene transfer protocols result in a small percentage of tumor cells being transduced in vivo, thus implicating a "bystander effect" to achieve therapeutic efficacy. Because bystander effects in the context of p53-mediated gene therapy have not been well characterized, we evaluated the role of in vitro and in vivo bystander effects of adenovirally delivered p53 (AdWTp53). Using human tumor cell lines that did not express p53 protein but were infectible with adenovirus and showed sensitivity to p53-mediated apoptosis, we were unable to demonstrate an AdWTp53-mediated in vitro bystander effect, despite seeing strong bystander effects when cells were infected with an adenovirus containing the suicide gene herpes simplex virus thymidine kinase and treated with ganciclovir. In contrast, in vivo flank mixing studies using one of these cell lines showed a weak but significant p53-mediated bystander effect (a 40% inhibition of tumor growth). This bystander effect translated into a small survival advantage in an established intraperitoneal tumor model when tumor burden was low at the time of viral instillation. The survival advantage was lost, however, when tumor burden was increased. This study indicates that treatment of human tumors using AdWTp53 may be possible; however, because of the weak bystander effect in vivo, effective treatment will likely require a large percentage of tumor cells to be transduced.
A potential strategy to treat cancer using gene therapy involves replacing a mutated tumor suppressor gene (e.g., p53) with its normal counterpart. Cell culture experiments show that introduction of wild-type (wt) p53 into tumor cells with either absent or mutated p53 leads to either growth arrest or cell killing. 1, 2 Because p53 has been shown to be the most frequently mutated gene in human cancers, 3 gene therapy using wt p53-containing vectors offers a potential treatment for tumors in vivo. 4 This paradigm has been tested in animal studies in which retroviruses, 5 adenoviral/polylysine/DNA complexes, 6 adenoassociated viruses, 7 cationic liposomes, 8 or adenoviruses 9 -13 containing wt p53 have been delivered in several malignancies. In many of these studies, p53-containing vectors alone 9 -12 or p53-containing vectors in combination with chemotherapeutic agents that enhance apoptosis (such as cisplatin) 13 showed some efficacy in decreasing the growth of tumors in vivo. These animal studies, in turn, have provided a rationale for human clinical trials. The results of a phase 1 trial in which a retrovirus-encoding p53 was repeatedly injected directly into lung tumor nodules was published recently. 14 This trial reported clinical evidence of tumor regression or stabilization in six of nine patients. A number of other p53-based gene therapy trials in humans using adenovirally delivered p53 to treat head and neck tumors, liver metastases, and brain tumors are being planned or are in the early stages of execution. 2 One puzzling aspect of an adenoviral-based gene therapy approach to cancer gene therapy in vivo has been the question of how effective tumor inhibition is achieved when it is known that only a minority of the tumor cells are infected with the current gene transfer protocols. Without a "bystander effect" (defined by the ability of transduced cells to kill adjacent nontransduced cells), it is difficult to understand how an introduction of p53 to a limited population of cells could be useful, because a selective growth advantage would be conferred to the nontransduced cells.
Bystander effects have been clearly demonstrated in other therapeutic approaches for cancer. For example, delivery of the "suicide gene" herpes simplex virus thymidine kinase (HSVtk) followed by treatment with ganciclovir (GCV) results in strong bystander effects due to the transfer of toxic metabolites via gap junctions, along with some less well-defined immunologic activation. 15 In contrast, the potential bystander effects operative in the context of p53 gene therapy have not been well characterized. The purpose of this study was to evaluate the bystander effects involved in AdWTp53-mediated cancer gene therapy. We sought to answer the following questions: (a) Is there a detectable in vitro bystander effect using p53 delivered by an adenoviral vector? (b) Is there a detectable in vivo bystander effect and, if so, how strong is this effect? and (c) What are the limits of efficacy of AdWTp53 in an animal model of established tumor?
MATERIALS AND METHODS

Cell lines
REN is a human mesothelioma cell line isolated from our laboratory; this cell line forms tumors in severe combined immunodeficient (SCID) mice after either intraperitoneal (i.p.) or subcutaneous (s.c.) injection. 16 H358 (a human bronchoalveolar carcinoma), U937 (human myelomonocyte leukemia cells), and 293 (E1a transformed human embryonic kidney cells) cell lines were obtained from the American Type Culture Collection (Manassas, Va). LP9, a normal mesothelial cell line, was obtained from the National Institute of Aging Cell Repository (Camden, NJ). LP9 was maintained in a 1:1 mixture of medium 199 Earle's Salt's and MCDB110 containing 15% fetal calf sera (FCS), 10 ng/mL epidermal growth factor, and 0.4 g/mL of hydrocortizone (Sigma, St. Louis, Mo). REN, H358, and U937 were maintained in RPMI 1640 modified medium (Life Technologies, Gaithersburg, Md) supplemented with 10% FCS, 100 U/mL of penicillin G, 100 g/mL streptomycin, and 200 mM glutamine. The 293 cells were maintained in Dulbecco's modified Eagle's medium (Life Technologies) supplemented with the same reagents as described for the RPMI 1640 medium.
Recombinant adenoviral vectors
The production of the E1/E3-deleted replication-deficient recombinant adenovirus encoding the human wt p53 gene has been described in detail previously. 17 The control adenoviral vectors expressing ␤-galactosidase (AdLacz) and AdHSVtk have been described previously. 16, 18 All adenoviral stocks were propagated in 293 cells as described previously, and titers were quantified by plaque assays. 18 The presence of wt virus was excluded by screening for the absence of E1a gene by polymerase chain reaction (PCR).
Adenoviral infection of cells
Cells seeded at 60 -80% confluence were infected with adenovirus at a multiplicity of infection (MOI) ranging from 0 to 200 in serum-free medium for 2 hours at 37°C; next, the media was supplemented with 10% FCS. To equalize for adenoviral infectibility, the relative infectibility of cells with adenovirus was assessed with a fluorescein di-galactosidase assay (Molecular Probes, Eugene, Ore) as described in detail elsewhere. 19 Briefly, at 20 -24 hours after infection with AdLacz at different MOIs, cells were reacted with fluorescein di-␤-D-galactopyranoside, a substrate for the galactosidase enzyme, and analyzed by flow cytometry (Epics XL, Coulter, Hialeah, Fla).
Northern blot analysis
REN cells were infected with AdWTp53 at MOIs of 10 and 50. After 20 hours, total RNA was isolated from infected as well as uninfected cells using the guanidine thiocyanate-phenol extraction method. 20 Total RNA from 293 and H358 cells was used as a control. A total of 20 g of total RNA was electrophoresed in a 1.2% agarose/2.2 M formaldehyde/3-(N-morpholino)propanesulfonic acid gel, and equal loading of RNA was confirmed by ethidium bromide staining. RNA was transferred onto a probe membrane (Bio-Rad, Hercules, Calif) and probed with either radiolabeled p53, p21, or mdm2 cDNA fragments (kindly provided by Dr. Donna George, Department of Genetics, University of Pennsylvania).
Southern blot analysis
The genomic structure of the p53 gene in various cell lines was analyzed by Southern blot analysis. Genomic DNA was isolated from 10 ϫ 10 6 H358, LP9, and REN cells by standard protocols. A total of 10 g of the DNA was digested with EcoRI, separated on 0.8% agarose gel, visualized by ethidium bromide staining, and recorded on a photograph. After transfer to the Zeta-probe membrane (Bio-Rad), the DNA was ultraviolet cross-linked and probed with radiolabeled p53 cDNA insert. This cDNA spanned part of exon 2 to part of exon 11. Exon 1 was not included in this insert.
Reverse transcriptase (RT)-PCR analysis
Total RNA was isolated from H358, LP9, 293, and REN cells as described previously. A total of 5 g of total RNA was reverse transcribed into cDNA with random primers using Maloney murine leukemia RT (Life Technologies, Gaithersburg, Md) according to the manufacturer's instructions. We used 5-L aliquots of the cDNA as templates for PCR to amplify 1.18 kilobases (kb) of p53 cDNA spanning the cDNA from exons 2-11. 21 The sense primer was 5Ј-atggaggagccgcagt-3Ј; the antisense primer was 5Ј-aatgtcagtctgagtcag-3Ј. PCR conditions were as follows: an initial denaturing step of 94°C for 3 minutes followed by 28 cycles at 94°C for 35 seconds, 47°C for 1 minute, and 72°C for 5 minutes. Negative controls were water, REN RNA with no RT, and H358 RNA.
Immunoblot analysis
REN cells were infected with AdWTp53 at MOIs of 1 and 10. After 18 hours, they were washed twice with phosphatebuffered saline (PBS) and scraped into 0.5 mL of 4ϫ Laemmli buffer. 22 To equalize for loading, 50 g of total protein, as measured by Lowry's method, was diluted in 100 L of 1ϫ Laemmli sample buffer containing ␤-mercaptoethanol. Proteins were separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, electrotransferred onto nitrocellulose membranes, immunoblotted with the p53 antibody (Pab-1801, Oncogene Research Products, Cambridge, Mass) at a dilution of 1/500, and visualized by enhanced chemiluminescence according to the manufacturer's instructions (Amersham, Arlington Heights, Ill).
Effect of AdWTp53 on cell growth
REN and H358 cells that had been plated at 60 -80% confluence were infected with AdWTp53 at MOIs of 50 and 200, respectively, to ensure 90 -95% infection of all cells. At 4 hours after supplementation with fresh medium, cells were washed twice with PBS, trypsinized, and plated onto six-well plates at a density of 4 -4.5 ϫ 10 4 cells/well. Cells were trypsinized from each well of a six-well plate daily and counted. For each type of infection, one six-well plate was counted each day (n ϭ 6). Toxicity due to the adenovirus alone was monitored by including a control virus, AdHSVtk.
Detection of apoptosis REN cells were plated onto 100-mm plates and infected 24 hours later with AdWTp53 at an MOI of 50. At 24 -36 hours postinfection, a proportion of the cells were floating in the medium. At this time, all cells were scraped into the medium and processed for DNA fragmentation analysis as described previously. 17 As a positive control, a similar analysis was performed on H358 cells that had been infected with AdWTp53 at an MOI of 200 to confirm the previously observed p53-mediated apoptosis in these cells. 17 In addition, U937 cells treated with 10 ng/mL of human recombinant tumor necrosis factor-␣ (TNF-␣) (Boehringer Mannheim, Indianapolis, Ill) for 3 hours at 37°C were used as a positive control for the DNA laddering assay. To evaluate for a non-p53-mediated apoptotic process, REN cells, which lack p53 protein, were heat-treated by trypsinizing cells and incubating 16 -18 hours in media at 42°C. The following day, cells were processed for DNA laddering.
In vitro mixing studies
Cells were infected at an MOI of AdWTp53 so that Ͼ90% of the cells were transduced and thus expected to undergo apoptosis. Following a 2-hour infection in serum-free medium, cells were washed thoroughly with PBS, fed fresh medium containing sera, and incubated for an additional 2 hours. Cells were thoroughly washed again with PBS to ensure complete removal of any unadsorbed virus. The washed and infected cells were trypsinized, mixed with similarly washed and trypsinized uninfected cells at varying ratios, and plated in 96-well plates. The total cell number per mixture was kept constant at 5,000 for REN cells and 10,000 for H358 cells.
A corresponding number of untransfected H358 or REN cells equivalent to the number of uninfected cells in a given ratio was also plated as a control for cell growth. Cell viability was monitored 3 days later using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) colorimetric cell proliferation assay (Promega, Madison, Wis). As a positive control for bystander effects, REN cells were infected with AdHSVtk at an MOI that ensured complete transduction. These cells were mixed with uninfected cells as described previously and plated in 96-well plates supplemented daily with 20 M of GCV. After 5 days, cells were subjected to MTT assay. As a control for the effects of non-p53-mediated apoptotic cell death, mixtures of heat-treated REN and untreated REN cells were plated in 96-well plates and assayed for cell viability 3 days later by MTT.
In vivo mixing study
The bystander study in vivo was evaluated by mixing equal numbers of AdWTp53-infected and uninfected REN cells ex vivo, according to the mixing regimen described for in vitro mixing studies. Three groups of five SCID mice per group were injected s.c. in both flanks (10 tumors/group) with 150 L of media containing the mixtures of infected and uninfected REN cells. The first group received 5 ϫ 10 6 AdWTp53-infected cells only; the second group received a mixture of 5 ϫ 10 6 AdWTp53-infected and 5 ϫ 10 6 uninfected cells; the third group received 5 ϫ 10 6 uninfected cells only. Animals were sacrificed 30 days later, and the flank tumors were excised and weighed. The tissues were frozen for additional evaluation. This experiment was repeated three times.
As a control for non-p53-mediated apoptosis, a separate study was performed in which equal numbers of heat-treated REN cells and untreated REN cells were mixed and placed into flanks. This study consisted of three groups, with five animals per group: (a) 5 ϫ 10 6 heat-treated cells, (b) a mixture of 5 ϫ 10 6 heat-treated cells and 5 ϫ 10 6 untreated cells, and (c) 5 ϫ 10 6 untreated cells only. Animals were sacrificed 30 days later, and the flank tumors were excised and weighed. This experiment was performed twice. In each set of experiments, tumor weights were normalized by dividing by the mean weight in the 5 ϫ 10 6 uninfected cell groups; an analysis of variance analysis was performed using the STATVIEW statistics software package (Berkeley, Calif).
Survival studies
Three survival studies were performed in which SCID mice received i.p. injections of 30 million REN cells suspended in 1 mL of media. After variable periods of time (study 1, 6 days; study 2, 11 days; or study 3, 14 days), tumor burden was confirmed in a single animal before the administration of the AdWTp53 virus. In each study, animals were randomly divided into three treatment groups, with 9 -10 animals per group. The first group was given media only, the second group was administered 1 ϫ 10 10 plaque-forming units of a control virus, AdLacz, and the third group was given 1 ϫ 10 10 plaqueforming units of AdWTp53. Viruses were administered by i.p. injection in 0.2-0.3 mL of media. Animals were observed closely and euthanized when signs of distress (as evidenced by severe weight loss, lethargy, paralysis, etc.) were noted. Survival of the animals was determined and plotted. Differences in mean survival among the three groups were analyzed by the Kruskal-Wallis test, followed by Mann-Whitney tests if significant differences (P Ͻ .05) were detected.
RESULTS
Characterization of p53 status in REN cells
To conduct the bystander studies, we required a human cell line that expressed defective or no p53 protein, was infectible by adenovirus, was susceptible to AdWTp53-mediated apoptosis, and grew well in mouse tumor models. We analyzed the p53 status of REN, a human mesothelioma cell line in which we have previously conducted studies with AdHSVtk, 16, 18 in comparison with a number of control cell lines.
To evaluate the status of the p53 gene, mRNA, and protein in REN cells, we performed an RT-PCR analysis on total RNA from REN cells. As shown in Figure 1A , p53 cDNA of 1.18 kb is not expressed in REN cells ( Fig  1A, lane 4) compared with the full-length transcript seen in 293 cells (Fig 1A, lane 3) . No p53 product was detected in the p53 null H358 cells as well (Fig 1A, lane  6) . The structure of the p53 gene in REN cells was shown to be rearranged as shown in Figure 1B , lane 1. Southern blot analysis of the genomic DNA from REN cells showed that the EcoRI fragment was smaller (by 1-1.5 kb) than the normal 15-kb band (Fig 1B, lane 2) .
The p53 gene was absent in H358 cells (Fig 1B, lane 3) . Digestion of DNA with EcoRI gives two 15-kb bands and one 3.5-kb band. 21 The 3.5-kb band was not detected, because the probe did not span this region. To additionally confirm the expression of mRNA, REN cells were subjected to Northern blot analysis. p53 mRNA was not detected in REN cells (Fig. 1C, lane 3) or in H358 cells (Fig 1C, lane 2) . A faint band of ϳ2-2.5 kb was detected in the 293 positive control.
The p53 protein status in the REN cell line was evaluated by immunoblot analysis using the anti-p53 Pab-1801 antibody that binds to both mutant and wt p53. Immunoblot analysis of REN showed no expression of p53 protein (Fig 1E, lane 1) compared with the positive control, 293 cells (Fig 1E, lane 4) . Moreover, these cells were refractory to induction of p53 as evidenced by the inability to up-regulate p53 in REN cells treated with either etoposide or irradiation (data not shown).
Having established that REN cells had an aberrant p53 gene, we subsequently evaluated whether REN cells could support AdWTp53 expression and function.
AdWTp53 is functional in REN cells
Although REN cells contained no endogenous p53 protein, they were able to sustain expression of exogenous p53 as seen in the immunoblot of REN cells infected with the AdWTp53 virus. Measurement of p53 protein by immunoblot analysis showed that p53 protein expression was up-regulated markedly in AdWTp53-infected cells (Fig 1E, lanes 2 and 3) , with none detected in uninfected cells (Fig 1E, lane 1) . Moreover, REN cells transduced at different MOIs of AdWTp53 expressed large amounts of p53 RNA by Northern blot analysis (Fig 1C, lanes 4 and 5) .
To determine whether the exogenous p53 was functional in REN cells, we measured the transcriptional activation of its two downstream target genes, namely p21 and mdm2.
1 Northern blot analysis of REN cells before and after infection with AdWTp53 at MOIs of 10 and 50 showed that uninfected REN cells produce little if any detectable p21 mRNA (Fig 1D, closed arrow, lane  3) . mdm2 RNA, which can be constitutively expressed at low levels, 23 was present in small amounts in these cells (Fig 1D, lane 3, open arrow) . However, following infection with AdWTp53, there was a marked up-regulation of both the p21 and mdm2 mRNAs (Fig 1D, lanes 4 and  5) . Similar results have been observed previously with H358 cells. 7, 13, 17, 24 Standardization of infectibility of cell lines with adenovirus Adenoviral transduction efficiency varies markedly between different cells due to differences in numbers of receptors and other unknown factors. 25 To standardize for equivalent adenoviral infection among different cell lines, we performed an inflexibility assay using an AdLacz virus. Results from this assay indicated that at an MOI of between 10 and 100, Ͼ90% of REN cells expressed the transgene (Fig 2, upper left panel) , whereas H358 cells were more resistant to adenoviral infection (Fig 2, upper right panel) .
AdWTp53 inhibits growth of REN cells
To study the consequences of high levels of p53 expression, we infected cells with AdWTp53 and determined the effects on cell growth. The growth characteristics of these cells are shown in the lower panels of Figure 2 . These data show that after AdWTp53 treatment, 75-90% of REN and H358 cells were killed by day 3. The contribution of viral toxicity toward cell killing was minimal, because cells infected with AdHSVtk at an equivalent MOI grew equally as well as uninfected cells.
AdWTp53 induces cell death by apoptosis
The mechanism of cell death due to high levels of p53 protein has been reported to be apoptosis. 1 To confirm this, we analyzed AdWTp53-infected cells for DNA fragmentation (Fig 3) . As a positive control, we assayed U937 cells treated with TNF-␣, which induces apoptosis in U937 cells and as expected, resulted in DNA laddering (Fig 3, lane 2 versus lane 3) . A typical pattern of DNA laddering was also seen in H358 cells (Fig 3, lane  8 versus lane 9) and REN cells (Fig 3, lanes 4 and 5 versus lane 6) infected with AdWTp53. In this study, we also evaluated a non-p53-mediated apoptotic method of cell killing. When heat-treated, REN cells were killed by apoptosis as shown by the DNA laddering in Figure 3 , lane 7. Therefore, we used heat-treated cells as a negative control in the mixing studies.
In vitro bystander studies In summary, the REN cell line seems to have no detectable p53 protein as measured by immunoblot analysis; exogenous p53 is functional in this cell line. Therefore, we used this cell line to perform the mixing studies to evaluate the bystander effects of p53. To study the bystander effects in vitro, a total of 5,000 REN cells or 10,000 H358 cells containing various mixtures of infected (or heat-treated) cells and uninfected cells were plated in 96-well plates; the cell growth was measured after 3 days using an MTT assay. As controls, duplicate wells containing equivalent numbers of uninfected cells were plated at the same time. Figure 4 depicts the relative cell numbers determined by MTT assay after 3 days of growth in culture for various mixtures of cells.
The control growth curves show the expected cell growth when varying numbers of uninfected REN cells (Fig 4A) and H358 cells (Fig 4E) were plated. A curve showing a strong positive bystander effect is illustrated in Figure  4B , in which 100% of infected AdHSVtk REN cells were mixed at varying ratios with uninfected cells and treated with 20 M of GCV. These results are consistent with our previously published data. 18 As a "negative" control, we used heat-treated REN cells (which undergo nonp53-mediated apoptosis, see Fig 3) and performed a similar mixing study. The growth curve (Fig 4C) for the groups of mixed cells was similar to that of uninfected cells (Fig 4A) .
The growth curves generated from mixing studies performed with either REN or H358 cells infected with ADWTp53 are shown in Figure 4D and F, respectively. These curves were not very different from those of uninfected cells, suggesting an absence of a bystander effect (Fig 4A) . The H358 cells were included because they have been used previously in AdWTp53 studies. 7, 13, 17, 24 In vivo bystander studies: s.c. tumor model To evaluate any possible interaction between the mixed cells in vivo, we conducted mixing studies in tumor models by essentially following the protocol that we have described previously for the evaluation of the HSVtk/ GCV system. 26 In these studies, five million uninfected REN cells were mixed with either five million REN cells infected ex vivo with a lethal dose of AdWTp53 or with five million REN cells that had been heat-treated ex vivo and injected into the flanks of SCID mice. The effect of injection of mixed cells on tumor size after 30 days was assessed. In the absence of a bystander effect, we would expect the tumor size to be unaffected by the coinjected cells. In the presence of an in vivo bystander effect, we would expect that the tumors would be smaller after coinjection.
The results of these experiments are shown in Figure  5 . Injecting uninfected tumor cells into the flanks of SCID mice led to easily measurable tumors after 30 days (range, 25-45 mg) (bars 1 and 4). No measurable tumors were detected in animals injected with either 5 million ex vivo AdWTp53-infected cells (bar 3) or heat-treated cells (bar 6). However, tumor growth was reduced by ϳ40% (P Ͻ 0.01) in animals inoculated with a 50:50 mixture of uninfected and AdWTp53-infected cells (bar 2). Tumor growth was not significantly affected in those animals inoculated with a mixture of uninfected and heat-treated cells (bar 5). These studies indicate that a detectable p53-mediated bystander effect is present in vivo. Comparing the tumor weights of the AdWTp53-treated REN mixtures (bar 2) with tumor weights of the heat-treated mixtures (bar 5), the degree of inhibition is 60%, suggesting that the AdWTp53-treated cells did not only inhibit tumor growth of the untreated cells, but also overcame the increased tumor mass due to the increased number of heat-treated cells. 
Survival studies
The presence of only a weak in vivo bystander effect in AdWTp53-mediated gene therapy suggests that high vector to tumor ratios will be required for successful tumor treatment. To test this hypothesis, we studied the therapeutic benefits of treatment with AdWTp53 in a mouse i.p. tumor model in which we have previously shown beneficial effects using the AdHSVtk/GCV system. 26 Three separate survival studies were performed in animals with differing amounts of established tumor. These survival studies were accomplished by inoculating SCID mice i.p. with the 30 million REN tumor cells followed by an i.p. injection of either media, AdLacz, or AdWTp53 at different intervals (6, 11, and 14 days) following tumor initiation. This strategy ensured a progressively larger tumor burden at the time of virus treatment as determined in the pretreatment autopsies.
In the first study (Fig 6A) , treatment was initiated on day 6. The mean survival of the p53-treated animals in this study was 30 days longer than media control (P Ͻ .004) and 15 days longer than AdLacz (P ϭ .02). The difference between survival in the media and LacZ groups was not significant (P ϭ .13). In the second study, treatment was delayed to day 11 ( Fig 6B) . In this study, there was no increased survival advantage in the p53 treatment group. In the third study, viral treatment was delayed until day 14 ( Fig 6C) . No survival advantage was seen in the p53-treated group; in fact, this group had a small decrease in mean survival compared with the control group (P ϭ .15) that was significantly shorter when compared with the AdLacz group (P ϭ .009). This difference was due to the unexplained deaths of three animals occurring within 2 days of AdWTp53 installation (Fig 6C) .
These studies indicate that with low tumor burden (i.e., a relatively high virus to tumor ratio), AdWTp53 confers some survival advantage. However, consistent with our observations that AdWTp53 induces only a weak bystander effect, as tumor burden increases (lower virus to tumor ratio), the survival advantage is lost.
DISCUSSION
This study evaluated the role of a bystander effect in AdWTp53-mediated gene therapy using approaches similar to those used in studying the suicide gene HSVtk/GCV system. Using a human tumor cell line that did not express p53 protein, was infectible with adenovirus, showed sensitivity to AdWTp53-mediated apoptosis in vitro, and grew well in both flank and i.p. tumor models in SCID mice, we demonstrated in mixing studies that AdWTp53-mediated gene therapy lacks an in vitro bystander effect in REN cells and in the previously studied H358 lung cancer line. In contrast, an in vivo flank mixing study showed a weak p53-mediated bystander effect (a 40% inhibition of growth). This weak bystander effect translated into a small survival advantage in an i.p. tumor model when tumor burden was low at the time of viral instillation. This survival advantage was lost when tumor burden was increased.
This lack of an in vitro bystander effect in two different cell lines is in contrast with the results of Cai et al, 24 who mixed uninfected H358 cells with H358 cells that had been infected with a retrovirus containing p53 and saw some inhibition in cell growth in vitro. These investigators interpreted that this finding was due to a small bystander effect, mediated possibly by a factor secreted by p53 apoptotic cells. A possible reason for the conflicting results could be the different vectors used. We have seen a similar lack of bystander effects in other cell lines tested by one of us, 27 and our results are consistent with a recently presented abstract 28 in which sarcoma cells infected with AdWTp53 also showed no in vitro bystander effect in a mixing study.
In contrast to the complete lack of bystander effects in vitro, we did observe a bystander effect in vivo by implanting a 50:50 mixture of AdWTp53 transfected and untransfected REN cells into the flanks of SCID mice. However, this effect was much weaker than that observed in our previous flank mixing studies in SCID mice using the AdHSVtk/GCV treatment model, in which tumor growth was completely abolished when only 10% of the cells were transduced. 26 The results of our experiments using AdWTp53 to treat established i.p. tumors of various sizes support the idea that only a weak bystander effect is present in vivo.
Thus, we saw a small but significant survival advantage in our first i.p. study when treatment was initiated 6 days following tumor implantation, at a time when there were no grossly visible tumor nodules and it was likely that a sizable percentage of tumor cells were infected with AdWTp53. In contrast, in our second and third i.p. tumor studies, when virus was injected 11 and 14 days after tumor implantation, there was no survival advantage. Although we did not formally establish what percentage of tumor cells were actually infected, p53 immunostaining of visible tumor nodules 1-2 days after tumor injection, with removal 1 day after viral instillation, showed positive p53 staining only at the periphery of the nodules (data not shown).
An important question relates to the mechanism(s) of the AdWTp53 bystander effect present in vivo. Although answering this question is beyond the scope of the present study, our data and the data of others do provide some suggestions. First, the in vivo bystander effect with p53 is not a simple reaction to the presence of apoptotic cells, as heat-treated apoptotic cells had no effect on the growth of untreated cells. Second, it is possible that the p53-treated tumor cells induce an immune response. In our SCID mice studies, the effector cells would be natural killer cells, macrophages, or neutrophils. However, in a pilot immunostaining study, we did not detect any significant inflammation in either control, AdLacz-, or AdWTp53-treated animals. The SCID mouse is not ideal for dissecting out the role of the immune component in the bystander effect. We are currently investigating the bystander effect in an immunocompetent mouse model. 27 Third, it is known that loss of p53 expression in tumor cells is correlated with an increased ability of the tumor to stimulate angiogenesis through a down-regulation of angiogenesis inhibitors such as thrombospondin 29 and other undefined angiogenesis inhibitors. 30 p53 also down-regulates the expression of a potent angiogenic stimulator-vascular endothelial growth factor. 31 Thus, re-expression of wt p53 could stimulate the production of thrombospondin and/or other angiogenesis inhibitors that would decrease the growth rate of the entire tumor. Although we stained the flank nodules from the mixing experiment for thrombospondin and vessel number and found no differences between control and mixed tumors, this evaluation was performed many days after tumor implantation and at a time when any early differences were likely to be nondetectable.
Two recent studies showing that the effectiveness of p53 therapy might be enhanced in situations in which longer term, low levels of p53 are induced are consistent with the idea that the bystander effect might be due to the antiangiogenic properties of p53 rather than to the induction of apoptosis. Xu et al 8 intravenously injected liposome/p53 complexes and showed a reduction in the growth rate of s.c. breast cancer nodules in nude mice, despite the fact that only a small number of tumor cells were infected at low levels of expression. Interestingly, some staining of a marker gene was seen in tumor endothelium, and vessels counts were lower in the p53-treated tumors. 8 A study by one of the co-authors Treatment was given as a single i.p. injection of AdWTp53 virus, AdLacz control virus, or media on day 6 (study 1) (A), day 11 (study 2) (B), and day 14 (study 3) (C) after tumor implantation. The survival of each group was determined. Each treatment group had 10 animals. Ⅺ, AdWTp53-treated animals; E, media-treated animals; ࡗ, AdLacz-treated animals. In study 1 (low tumor burden) (A), there was a small but significant increase in survival in the p53-treated animals compared with media controls (P Ͻ .004) and AdLacztreated animals (P ϭ .02). In studies 2 and 3 (higher tumor burdens) (B,C), no significant survival advantage was present.
(P.S.) using adenoassociated virus to transduce p53 into tumors also demonstrated impressive antitumor effects, although the levels of p53 expression per cell were much less than that induced by the adenovirus. 7 The results of both of these studies are consistent with the hypothesis that having cells express lower levels of p53 for longer periods (i.e., a situation in which very rapid induction of apoptosis is not induced) might allow for a longer production of antiangiogenesis factors and thus be more effective in inhibiting tumor growth. Additional studies to further define these and other potential mechanisms are required.
The most important implication of this study is that although AdWTp53-mediated gene therapy may be effective in killing transduced tumor cells, effective treatment of tumors using this approach will likely require that a large percentage of the malignant cells be transduced because of the weak bystander effect.
One approach that might be useful is ex vivo treatment of tumor cells. For example, one of us (P.S.) has recently shown that bone marrow purging of malignant cells using AdWTp53 in the setting of bone marrow transplant for refractory breast cancer might be a useful therapeutic approach. 32 With regard to the treatment of solid tumors, treatment strategies that promote the transduction of a large percentage of tumor cells will have to be used. In this context, it is interesting to review studies in which the in vivo sensitivity of tumor to AdWTp53 has been evaluated. Consistent with our findings, studies using a single administration of p53 vectors in established tumors have reported limited success. 6, 7, 10, [33] [34] [35] In the one study that did treat established i.p. ovarian cancer nodules in a model similar to ours, the authors found that the mean survival of treated animals was not extended; however, there were a few long-term survivors in the p53-treated animals. 12 In contrast, most of the studies in which significant antitumor effects have been reported have used methods to obtain high virus to tumor ratios by: (a) transfecting the tumors ex vivo and then implanting them, 11, 12, 36, 37 (b) making multiple direct injections of vector at multiple timepoints into established tumors, 11, 12, 33, 37, 38 or (c) treating the tumor with the virus very early after tumor establishment. 35 In conclusion, this study indicates that the treatment of human tumors using AdWTp53 may be possible; however, because of the weak bystander effect, effective treatment will likely require a large percentage of tumor cells to be transduced. Thus, our results suggest that the most effective treatment strategies will be those that incorporate ex vivo transduction (i.e., bone marrow purging), those that are aimed at treating residual disease, or those in which specific anatomic conditions provide ways of infecting large numbers of tumor cells (i.e., hepatic artery injection to infect liver metastasis). 39 
